

08-19-04

12W



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sharen A. Godwin

Serial No.: 10/800,876

Filed: March 15, 2004

Group: 3621

For: METHOD OF IDENTIFYING CLINICAL TRIAL PARTICIPANTS

Honorable Director of Patents and Trademarks

Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In keeping with the duty of candor and good faith owed to the Patent and Trademark Office, the applicant wishes to make of record the references on attached PTO/SB/08A form. Copies of the items are provided in accordance with 37 C.F.R. 1.98.

The subject invention differs considerably in appearance and design from the features disclosed in the above references. For these reasons it is respectfully submitted that the instant invention is patentable over these references. These are submitted to the Patent Office only to ensure that all related art of which applicant is aware is before the examiner for consideration.

Respectfully submitted,

William J. Mason

Registration No. 22,948

Date: August 18, 2004

File No.: 5714-001

PTO SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 1

Complete if Known

Application Number 10/800,876
Filing Date 03/15/2004
First Named Inventor Sharen A. Godwin
Art Unit 3621
Examiner Name
Attorney Docket Number 5714-001

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 6055494	04-25-2000	Friedman	
		US- 6182029	01-30-2001	Friedman	
		US- 6272481	08-07-2001	Lawrence et al.	
		US- 6385589	05-07-2002	Trusheim et al.	
		US- 6151581	11-21-2000	Kraftson et al.	
		US- 5903889	05-11-1999	de la Huerga et al.	
		US- 6230142	05-08-2001	Benigno et al.	
		US- 6438533	08-20-2002	Spackman et al.	
		US- 5772585	06-30-1998	Lavin et al.	
		US- 6611846	08-26-2003	Stoodley	
		US- 5832450	11-03-1998	Myers et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Honorable Director of Patents and Trademarks
Washington, D.C. 20231

Sir:

CERTIFICATE OF MAILING/EXPRESS MAIL

"Express Mail" Mailing Label Number : EL975046181US

Date of Deposit: August 18, 2004

I hereby certify that this paper(s), which is an Information Disclosure Statement and Form PTO/SB/08A for U.S. Patent Application Serial No. 10/800,876 entitled METHOD OF IDENTIFYING CLINICAL TRIAL PARTICIPANTS is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

William J. Mason
Registration No. 22,948

Our File No. 5714-001

Mailed By: 